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for a randomised controlled trial
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Abstract
Background: Ventilator-acquired pneumonia (VAP) is a common reason for antimicrobial therapy in the intensive
care unit (ICU). Biomarker-based diagnostics could improve antimicrobial stewardship through rapid exclusion of
VAP. Bronchoalveloar lavage (BAL) fluid biomarkers have previously been shown to allow the exclusion of VAP with
high confidence.
Methods/Design: This is a prospective, multi-centre, randomised, controlled trial to determine whether a rapid
biomarker-based exclusion of VAP results in fewer antibiotics and improved antimicrobial management. Patients
with clinically suspected VAP undergo BAL, and VAP is confirmed by growth of a potential pathogen at > 104
colony-forming units per millilitre (CFU/ml). Patients are randomised 1:1, to either a ‘biomarker-guided recommendation
on antibiotics’ in which BAL fluid is tested for IL-1β and IL-8 in addition to routine microbiology testing, or to
‘routine use of antibiotics’ in which BAL undergoes routine microbiology testing only. Clinical teams are blinded
to intervention until 6 hours after randomisation, when biomarker results are reported to the clinician. The primary
outcome is a change in the frequency distribution of antibiotic-free days (AFD) in the 7 days following BAL. Secondary
outcome measures include antibiotic use at 14 and 28 days; ventilator-free days; 28-day mortality and ICU mortality;
sequential organ failure assessment (SOFA) at days 3, 7 and 14; duration of stay in critical care and the hospital;
antibiotic-associated infections; and antibiotic-resistant pathogen cultures up to hospital discharge, death or 56 days.
A healthcare-resource-utilisation analysis will be calculated from the duration of critical care and hospital stay. In
addition, safety data will be collected with respect to performing BAL. A sample size of 210 will be required to
detect a clinically significant shift in the distribution of AFD towards more patients having fewer antibiotics and
therefore more AFD.
Discussion: This trial will test whether a rapid biomarker-based exclusion of VAP results in rapid discontinuation
of antibiotics and therefore improves antibiotic management in patients with suspected VAP.
Trial registration: ISRCTN65937227. Registered on 22 August 2013. ClinicalTrials.gov, NCT01972425. Registered
on 24 October 2013.
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Background
Patients admitted to the intensive care unit (ICU)
constitute a group vulnerable to healthcare-associated
infection (HCAI), and consistent with that, antibiotic
consumption in the ICU is considerably higher than
in other hospital environments [1]. The growing global
challenge of antimicrobial-resistance requires improved
antibiotic stewardship. This judgment is, however, chal-
lenging in critically ill patients in whom clinical signs of
infection are non-specific and where the consequences
of missing a treatable infection may be significant.
Ventilator-acquired pneumonia (VAP) is a common
ICU HCAI and highlights the challenges of antibiotic
stewardship. Few clinical features have a specificity of
greater than 60 % [2–4], and infection is confirmed
in approximately 40 % of patients with suspected
VAP [5]. The majority of patients with suspected
VAP have antibiotics started at the point of clinical
suspicion and de-escalation or discontinuation of anti-
biotics is possible after 2–3 days, when culture informa-
tion becomes available. During this period, a significant
proportion of patients will receive antibiotics that may
not be indicated, and furthermore, if antibiotics are not
discontinued in light of negative cultures, a full course
of unnecessary antibiotics may be administered.
Addressing limitations in diagnostic methods for
infections has the potential to improve antibiotic
management by expediting the diagnostic process.
Biomarkers of infection can act as rapid surrogate
markers. In a recent multi-centre observational study
[5], we validated the findings of a single-centre-
derivation study [6, 7], showing that bronchoalveolar
lavage (BAL) fluid biomarkers could form a reliable
test to exclude VAP. Low concentrations of BAL fluid
interleukin 1-beta (IL-1β) consistently have a strong
negative predictive value (NPV) in both the derivation
and validation cohorts. Furthermore, in the validation
cohort, a combination of IL-1β and IL-8 could be
used as a biomarker test to rule out VAP with high
confidence, with a NPV of 1 and a post-test probabil-
ity of 0 % (95 % confidence interval 0–9.2 %). These
biomarkers are measured by cytometric bead array (CBA),
which is a multi-plex, flow cytometric application that can
be performed in approximately 6 hours, offering the po-
tential for a rapid biomarker-based test in the ICU.
The aim of this randomised trial is to determine if,
in adult patients with suspected VAP, the use of the
additional rule-out biomarker test will improve antibiotic
management and reduce antimicrobial use in comparison
to decision making based on microbiology results alone.
Methods/Design
This protocol outlines a multi-centre, prospective,
controlled trial in which patients with suspected VAP
are randomised 1:1 to a rapid biomarker-rule-out test
in addition to standard care, compared to standard
care alone (clinical judgment plus standard microbio-
logical culture). The primary outcome measure is
antibiotic-free days (AFD) in the 7 days following
BAL. This clinical trial adheres to the Consolidated
Standards of Reporting Trials statement (Fig. 1) [8]
and principles of Good Clinical Practice.
Study population
Participants are being recruited from the ICUs of 17
National Health Service (NHS) Trusts in the UK, for a
total of 22 ICUs. These ICUs cover a broad case mix of
medical, surgical and trauma patients, who are represen-
tative of current practice across the NHS.
Patients with suspected VAP who are at least 18 years of
age, intubated and mechanically ventilated for 48 hours or
more are considered eligible for inclusion in the trial. VAP
is suspected based on the presence of a new or worsening
chest X-ray or computed tomography (CT) changes
consistent with pneumonia in the context of at least two
of the following: temperature < 35 °C or > 38 °C; a white
cell count of < 4 × 109 / L or > 11 × 109 / L; or purulent
tracheal secretions [9]. Patients must also be consid-
ered suitable for early discontinuation of antibiotics by
the clinical team (i.e. have no extra-pulmonary source
of infection that mandates the use of continued
antibiotics).
Patients are excluded on the basis of previously
published criteria [10] that predict poor tolerance of the
bronchoscopy and BAL that have been previously ap-
plied in our studies [5, 7]. These are: PaO2 < 8kPa on a
FiO2 > 0.7; positive end-expiratory pressure of > 15 cm
H2O; peak airway pressure > 35 cm H2O; heart
rate > 140 beats per minute; mean arterial pressure
< 65 mmHg; bleeding diathesis including platelet count
< 20 × 109/L or international normalised ratio (INR) > 3;
poorly controlled intracranial pressure (>20 mmHg); or
ICU consultant deems the procedure not to be safe.
Patients may only be randomised to the study once
(i.e. they are excluded if they have had previous BAL as
part of the study). Patients are also excluded if assent/
consent is declined.
Co-enrolment is allowed with observational studies.
Co-enrolment with interventional studies is allowed
following consideration of any scientific or statistical
interactions in accordance with current UK recommen-
dations [11].
Biomarker assay and laboratory set up
The biomarker assay is performed in six NHS or
university laboratories that act as testing ‘hubs’. Par-
ticipating ICUs had to be within an expected travel
time of 1.5 hours of a hub. BAL fluid samples are
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transported to the laboratory on ice immediately after
sampling and measurement of BAL fluid IL-1β and
IL-8 by cytometric bead array is performed with min-
imal delay on arrival. IL-1β and IL-8 are combined by
logistic regression by the equation, established in the
validation study [5]:
−2:7385 þ 1:4633  log10 1 þ IL−1βð Þ−0:2721
 log10 1 þ IL−8ð Þ
VAP is excluded if the regression output falls below a
defined level (-1.7616).
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) 2010 flow diagram
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All equipment, reagents and ongoing maintenance
are supplied by the study’s industry partner, Becton
Dickinson Biosciences (Franklin Lakes, NJ, USA). Each
hub has been issued an Accuri C6 flow cytometer. This
is a benchtop flow cytometer designed for its ease of
use. The biomarker assay and all Accuri standard oper-
ating procedures (SOPs) have been designed such that
they can be carried out by healthcare service laboratory
technicians with limited flow cytometry experience.
Centralised training in the biomarker assay and Accuri
C6 was provided by investigators and scientists from
Newcastle University and Becton Dickinson.
Accuri quality control tests are performed once a week
by each hub, and these data are monitored by the flow
cytometry core facility in Newcastle University. Technical
support is provided by the investigators at Newcastle
University and by Becton Dickinson.
Intervention
All patients enrolled in the trial have suspected VAP and
undergo the same clinical procedures of bronchoscopy
and BAL. The BAL is performed according to a previ-
ously described SOP [5].
Patients are randomised to have BAL samples analysed
by either the biomarker test in addition to semi-
quantitative culture (the intervention arm) or semi-
quantitative cultures alone (the control arm). The
intervention arm is referred to as the ‘biomarker-guided
recommendation on antibiotics’ group and the control
arm the ‘routine use of antibiotics’ group. All semi-
quantitative cultures are performed in a NHS or Public
Health England laboratory and handled by a SOP in
accordance with the UK Standards for Microbiological
Investigation [12]. VAP is confirmed by the widely used
threshold of growth of a potential pathogen at > 104
colony-forming units per ml (CFU/ml) [13].
Biomarker results are reported to the clinical team by
the technician using a standard script after approximately
6 hours. It is anticipated that all patients would have anti-
biotics started at the point of suspicion of VAP. In the
event of a biomarker result that falls below the cut-off
value, the clinical team is advised that VAP is excluded
with high confidence and that early discontinuation of
antibiotics is advised. If the biomarker value is above
the threshold the clinical team is advised that VAP
cannot be excluded and that standard care should
continue.
Risk to participants
Patients enrolled in this trial are by definition critically
unwell, and minimising the risk to these patients is of
paramount importance. BAL is an established and widely
used technique for sampling the alveolar regions in ICU
patients [13, 14]. Not only do eligibility criteria exclude
patients who would poorly tolerate a BAL, but patients
can be excluded based on the clinicians’ judgment of the
risk profile.
The second consideration of risk is around the early
discontinuation of antibiotics. The risk exists that antibi-
otics may be incorrectly discontinued in the face of
undetected infection (i.e. in the setting of a false negative
biomarker test). The validation study demonstrated that
the threshold for excluding VAP using BAL IL-1β and
IL-8 had an NPV of 1 which gives confidence in the
test’s performance, but with a 95 % confidence interval
of 0.92–1.0 false negatives remaining possible. Decisions
around antibiotic prescribing are not dictated by the trial
protocol, and these ultimately remain at the discretion
of the treating clinician. This allows the clinician to
restart antibiotics if it is felt they were discontinued in-
appropriately. This minimises the risk to patients and
also makes the trial more pragmatic, testing its use in
‘real life’ clinical practice.
Primary outcome and sample size
The primary outcome measure is the frequency distribu-
tion of AFD in the 7 days following BAL. This interval
was used as this is the average reported duration of
antibiotic therapy for suspected VAP in UK practice
[15]. For the purposes of study design, AFD can be
considered to be an integer value with patients in one of
eight categories (0–7 AFD). Fewer days of antibiotic
treatment will be detected as an increase in the propor-
tion of patients with higher numbers of AFD and fewer
patients having zero AFD. Antimicrobials delivered for
prophylaxis will be excluded from analysis.
The sample size is based on the frequency distribution
of AFD in the 7 days after BAL in our previous valid-
ation study. This baseline distribution of AFD showed a
skew towards patients with suspected VAP having few
or no AFD (with this effect manifest both in those with
ultimately confirmed VAP and those in whom BAL
microbiology did not confirm VAP). We modelled
changes in the distribution of AFD from baseline to a
distribution with more patients having higher numbers
of AFD. Table 1 gives examples of the different
frequency distributions and their effect sizes. We judged
a distribution that equates to effect sizes above 0.07
would represent a clinically important difference. By
way of illustration, this would be equivalent to a change
from a baseline median of 0 AFD (interquartile range
0–2.5 AFD) to a median of 1.5 AFD (interquartile range
0–3.5 AFD) under biomarker-guided treatment. An effect
size of 0.0797 requires 90 patients per trial arm and allow-
ing for a 15 % drop out, the total sample size is 210. This
outcome measure and effect size was presented for
national stakeholder peer review and judged to be
appropriate (UK Critical Care Research Forum, July 2013).
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Figure 2 illustrates the changes in the AFD
distribution between baseline and model 3 from
Table 1.
Secondary outcome measures
Secondary outcome measures will include antibiotic
days and AFD, expressed as continuous variables, at
7, 14 and 28 days; ventilator-free days at 28 days; 28-day
mortality and ICU mortality; sequential organ failure
assessment (SOFA) score at days 3, 7 and 14; duration of
level 2 (high dependency unit) care, level 3 (intensive care
unit) care and hospital stay; Clostridium difficile and
MRSA infections up to hospital discharge, death or
56 days; and antibiotic-resistant pathogen cultures up to
hospital discharge, death or 56 days. A healthcare-re-
source-utilisation analysis will be calculated from the dur-
ation of level 2 care, level 3 care and hospital stay up to
discharge, death or 56 days.
Since this is a trial of a complex intervention, a
process evaluation will be carried out in parallel with
this trial. This will evaluate the process of conducting
the trial and will aim to determine reasons for poten-
tial discrepancies in the expected and observed trial
outcome, as well as providing information on the po-
tential implementation of the intervention after trial
completion. Additional files outline the detailed study
protocol for the process evaluation (see Additional
files 1 and 2).
Data collection
Data are collected on the day of enrolment (day 0); day
3; day 7; day 14; day 28; and date of discharge, death or
at 56 days. Clinical data collected include the age,
gender, date of admission to the hospital and ICU,
reason for admission to the hospital and ICU, functional
comorbidities index, acute physiology and chronic health
Table 1 Models of different frequency distribution of AFD. Standard care distribution is based on data obtained from our validation
cohort. The different models demonstrate increasing shifts in the frequency distribution towards more AFD in the sample. These
distributions are illustrative, and different proportions in each category could give the same effect size. AFD antibiotic-free days
Proportion of AFD (%)
0 1 2 3 4 5 6 7 N per arm Effect size
Standard Care (from validation study) 55 10 10 5 5 5 5 5
Model 1 40 20 15 5 5 5 5 5 215 0.033
Model 2 35 20 15 10 5 5 5 5 138 0.052
Model 3 30 20 15 10 10 5 5 5 96 0.075
Model 4 25 20 20 10 10 5 5 5 68 0.106
Fig. 2 Graphical representation of the shift in distribution in antibiotic-free days (AFD) between baseline and model 3
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evaluation (APACHE) 2 score at admission, SOFA score,
time from MV to suspected VAP, and pathogens
cultured from BAL.
Safety measures will be recorded relative to the bron-
choscopy and BAL. These will include SaO2, heart rate,
blood pressure and PaO2:FiO2. Biological data will in-
clude concentrations of IL-1β and IL-8 in the BAL fluid
for patients who are randomised to the intervention
arm.
Recruitment process and consent
All patients on the participating ICUs are screened on
weekdays for eligibility. Potentially eligible patients are
discussed with the ICU consultant to determine the
appropriateness of early discontinuation of antibiotics
and whether any other safety concerns are present that
would exclude the patient.
Consent and assent procedures are in keeping with the
legal framework of England, Northern Ireland (Mental
Capacity Act, 2005) or Scotland (Adults with Incapacity
(Scotland) Act, 2000) for consent/assent of adults without
capacity. In England and Northern Ireland informed
assent is obtained, where possible, following discussion
with the patient’s next of kin (personal consultee). Where
a personal consultee is unavailable, assent is provided by a
nominated consultee, usually the ICU consultant, provid-
ing they are not also a member of the research team. In
circumstances where the next of kin are unable to attend
the ICU promptly, eliciting their opinion is possible by
telephone to inform nominated assent.
In Scotland the patient’s relative or welfare attorney
provides the informed consent. If the patient’s relative or
welfare attorney is unable to attend the ICU, consent
may be provided in a telephone conversation, providing
a second member of staff witnesses the discussion.
Patients who recover capacity will be approached to
provide retrospective informed consent. The decision as
to whether that patient has regained capacity will reside
with the treating team. The patient will be given suffi-
cient time to consider the trial information before pro-
viding their consent to continued trial involvement.
Randomisation and blinding
Once consent/assent is obtained, the clinical team
informs the laboratory technician who will perform the
biomarker test, and the technician then initiates ran-
domisation through the Newcastle Clinical Trials Unit
(NCTU). Randomisation is performed using a web-
based randomisation service. Patients are randomised to
the intervention arm or control arm in a 1:1 ratio by
permuted blocks of variable length and stratified by site.
The randomisation service generates either an instruc-
tion that the patient is randomised to ‘biomarker-guided
recommendation on antibiotics: analyse sample on arrival’
or to ‘routine use of antibiotics: do not analyse sample
on arrival’. This message is emailed to the technician.
The clinical team is initially blinded to the trial arm
since all trial procedures are performed in all partici-
pants. Unblinding occurs when the biomarker result
is called back to the clinical team after approximately
6 hours. To ensure consistency in unblinding, after
this period, the clinical team are also informed if the
patient was randomised to the control arm. The tech-
nician contacts the clinical team with the results
according to local arrangements, which include con-
tacting the on-call ICU consultant, ICU resident or
the local principal investigator.
Statistical analysis
Baseline clinical data will be compared between trial
arms for balance using graphical and summary statistics
appropriate for the data type of each variable. No formal
tests of equality will be carried out. The primary out-
come measure will be analysed by a chi-squared test on
a 2 × 8 table of study arm versus AFD categories.
Secondary outcome measures will be analysed by fitting
appropriate generalised linear models with intervention
and centre as covariates. Link functions will be deter-
mined by the type of outcome variable. A sub-group
analysis for patients with trauma or head injury will be
included as will a sub-group analysis based on clinician
assessment of likelihood of VAP. Data analysis will be
performed on an intention-to-treat basis, although other
exploratory analyses including per-protocol analysis will
be considered. A per-protocol analysis will be per-
formed excluding patients who were randomised to
the biomarker-guided recommendation on antibiotics
arm, but who had a technical issue with the assay and
therefore defaulted to standard care.
A within-trial cost analysis will be undertaken to assess
the hospital resource use from the point of randomisation
until hospital discharge or death, whichever occurs first,
for a maximum of 56 days. Patient-level hospital resource
use will be estimated from length of ICU stay and length
of hospital stay. Multiple regression analyses will be
performed to examine patient factors, which are poten-
tially associated with costs. The robustness of the re-
sults will be evaluated using sensitivity analyses.
Monitoring and adverse event reporting
A Data Monitoring and Ethics Committee will have
oversight of the trial. This is an independent body that
has oversight of safety data. They will make recommen-
dations to the sponsor as to whether the trial should
progress, be modified or terminated.
NCTU will monitor adherence to the trial protocol
and completeness of the data collection. Adverse events
(AE) and serious adverse events (SAE) that occur within
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2 hours of BAL are reported to NCTU. Site investigators
are able to report an AE/SAE outside of this period if
they feel an AE/SAE is related to the study.
Trial approvals, registration and status
Ethics approval for this trial has been granted by the
National Research Ethics Service (England and Northern
Ireland, Camberwell St Giles Committee, 13/LO/0651)
and by the Scotland A Research Ethics Committee (13/
SS/0074). Local research governance approval has been
granted in the 17 NHS Trusts in which the trial is con-
ducted: The Newcastle Upon Tyne NHS Foundation
Trust; City Hospitals Sunderland NHS Foundation
Trust; Heart of England NHS Foundation Trust; Salford
Royal NHS Foundation Trust; Chelsea and Westminster
NHS Foundation Trust; Lancashire Teaching Hospitals
NHS Foundation Trust; Belfast Health and Social Care
Trust; NHS Lothian; Countess of Chester NHS Founda-
tion Trust; Northumbria Healthcare NHS Foundation
Trust; University Hospitals Coventry and Warwickshire
NHS Trust; Royal Liverpool and Broadgreen University
Hospitals NHS Trust; Gateshead Health NHS Foundation
Trust; Sandwell and West Birmingham Hospitals NHS
Trusts; The Dudley Group of Hospitals NHS Foundation
Trust; Central Manchester Hospitals NHS Foundation
Trust; and South Tees Hospitals NHS Foundation Trust.
The trial is registered on the ISRCTN registry (65937227)
and on ClinicalTrials.gov (NCT01972425).
Discussion
Limitations in diagnostic techniques to correctly rule-in
or rule-out infections results in many patients receiving
unnecessary antibiotics. Successfully validating the use
of BAL fluid IL-1β and IL-8 to exclude VAP has been a
significant step forward for developing diagnostics in
this area [5]. A rapid rule-out of VAP should allow for
discontinuation of antibiotics on the day of suspicion of
VAP and therefore improve antibiotic management. This
randomised controlled trial aims to determine the clinical
utility of a rapid biomarker-based test by measuring
the antibiotic use, which is expressed as AFD, in the
7 days that follow BAL.
Few biomarkers are used in the ICU to guide anti-
biotic management, and none specifically for VAP. Due
to the novelty of the biomarker and the conduct of this
trial in a complex clinical environment, regular educa-
tion and reinforcement of the trial protocol is necessary
with participating sites. Furthermore, the trial method-
ology accommodates the complexity of the intervention
by including elements such as the process evaluation.
This trial represents a potentially important step
forward for novel diagnostics in the ICU. If effective in
its primary outcome it could result in an important im-
provement in antimicrobial stewardship in this patient
group. It also represents a challenging and complex trial
of novel diagnostics in a difficult clinical space. The
process of conducting this trial will provide valuable
information to inform future trials.
Trial status
The trial is currently active in all participating sites. The
first patient was recruited in December 2013, and the
trial is due to complete in 2016.
Additional files
Additional file 1: Process evaluation of the implementation and delivery
of the VAPrapid-2 trial. Process evaluation protocol. (DOCX 33.9 kb)
Additional file 2: VAPrapid-2 Logic Model. (PDF 87 kb)
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